Toxicity in a double-blind, placebo-controlled pilot trial with D-penicillamine and metacycline in secondary progressive multiple sclerosis

Multiple Sclerosis

Volumn 4, Issue 2, 1998, Pages 74-78

  Dubois, B ^a   D'Hooghe, M B ^b   De Lepeleire, K ^b   Ketelaer, P ^b   Opdenakker, G ^a   Carton, H ^c  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b National Multiple Sclerosis Center   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

D penicillamine; Metacycline; Metalloproteinase inhibition; Multiple sclerosis; Pilot study

Indexed keywords

ANTIRHEUMATIC AGENT; GELATINASE B; METACYCLINE; MONTEPLASE; PENICILLAMINE; TETRACYCLINE DERIVATIVE;

ADULT; ARTICLE; BLOOD BRAIN BARRIER; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMYELINATION; DEPRESSION; DIARRHEA; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; ENZYME INHIBITION; FEMALE; FOLLOW UP; GAIT DISORDER; HEADACHE; HUMAN; HYPOGEUSIA; LEUKOPENIA; MALE; MULTIPLE SCLEROSIS; NAUSEA; PATIENT COMPLIANCE; PROTEINURIA; PRURITUS; RANDOMIZED CONTROLLED TRIAL; TASTE DISORDER; TOOTH COLOR;

EID: 0031966055     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/135245859800400206     Document Type: Article

References (22)

1. Rinne UK, Riekkinen P. (1968) Esterase, peptidase and proteinase activities of human cerebrospinal fluid in multiple sclerosis. Acta Neurol Scand 44: 156 - 167.
2. Cuzner ML, Davison AN, Rudge P. (1978) Proteolytic enzyme activity of blood leukocytes and cerebrospinal fluid in multiple sclerosis. Ann Neurol 4: 337 - 334.
3. Martin R, McFarland HF, McFarlin DE. (1992) Immunological aspects of demyelinating diseases. Annu Rev Immunol 10: 153 - 187.
4. Cuzner ML et al. (1996) The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. J Neuropathol Exp Neurol 55 (12): 1194 - 1204.
5. Prineas JW, Kwon EE, Cho E, Sharer LR. (1984) Continual breakdown and regeneration of myelin in progressive multiple sclerosis plaques. Ann NY Ac Sciences 436: 11 - 32.
6. Hayes GM, Woodroofe MN, Cuzner ML. (1987) Microglia are the major cell type expressing MHC Class II in human white matter. J Neurol Sciences 80: 25 - 37.
7. Masure S, Proost P, Van Damme J, Opdenakker G. (1991) Purification and identification of 91-kDa neutrophil gelatinase. Eur J Biochem 198: 391 - 398.
8. Paemen L et al. (1994) Evaluation of gelatinases and IL-6 in the cerebrospinal fluid of patients with optic neuritis, multiple sclerosis and other inflammatory neurological diseases. European Journal of Neurology 1: 55 - 63.
9. Maeda A, Sobel RA. (1996) Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J Neuropathol Exp Neurol 55: 300 - 309.
10. Proost P, Van Damme J, Opdenakker G. (1993) Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. Biochemical and Biophvsical Research Communications 192: 1175 - 1181.
11. Opdenakker G, Van Damme J. (1994) Cytokine-regulated proteases in autoimmune diseases. Immunology Today 15: 103 - 107.
12. Paemen L et al. (1996) The gelatinase inhibitory activity of totracyclines and chemically modified tetracycline analogues as measured by a novel microtiter assay for inhibitors. Biochemical Pharmacology 52: 105 - 111.
13. Norga K et al. (1996) Human gelatinase B, a marker enzyme in rheumatoid arthritis, is inhibited by D-penicillamine: anti-rheumatic activity by protease inhibition. Clinical Rheumatol 15: 31 - 34.
14. Norga K et al. (1995) Prevention of acute autoimmune encephalomyelitis and abrogation of relapses in murine models of multiple sclerosis by the protease inhibitor D-penicillamine. Inflamm Res 44: 529 - 534.
15. Sibley WA and the Therapeutic Claims Committee of the International Federation of Multiple Sclerosis Societies (1996) Therapeutic claims in multiple sclerosis, a guide to treatments, fourth edition. Demos Vermande p 41.
16. Gijbels K, Masure S, Carton H, Opdenakker G. (1992) Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J Neuroimmonol 41: 29 - 34.
17. Akenami FOT et al. (1996) Cerebrospinal fluid activity of tissue plasminogen activator in patients with neurological diseases. J Clin Pathol 49: 577 - 580.
18. Gijbels K, Galardy RE, Steinman L (1994) Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. J Clin Invest 2177 - 2182.
19. Brosnan CF, Cammer W, Norton WT, Bloom BR. (1980) Proteinase inhibitors suppress the development of experimental allergic encephalomyelitis. Nature 285: 235 - 237.
20. Hewson AK, Smith T, Leonard JP, Cuzner ML. (1995) Suppression of experimental allergic encephalomyelitis by the matrix metalloproteinase inhibitor Ro31-9790, Inflamm Res 44: 345 - 349.
21. Gabler WL, Creamer HR. (1991). Suppression of human neutrophil functions by tetracyclines. J Periodont Res 26: 52 - 58.
22. Paemen L, Martens E, Masure S, Opdenakker G. (1995) Monoclonal antibodies specific for natural human neutrophil gelatinase B used for affinity purification, quantitation by two-site ELISA and inhibition of enzymatic activity. Eur J Biochem 234 (3): 759 - 765.